Full mechanism, in text

Too much iron is possible

1 · Normal HFE-hepcidin loop

The body cannot actively excrete iron, so liver cells, sensing iron through HFE and other sensors, adjust hepcidin to set how much iron the gut lets in.Iron absorption is the opposite of most nutrients — the body has no active iron excretion mechanism. Daily net loss is only 1-2 mg (sloughed enterocytes + sweat + minimal urinary loss). So iron homeostasis is controlled entirely by "how much we let in."

How this gate works:

· Enterocytes in the small intestine carry DMT1 on the apical side to bring luminal iron into the cell.
· On the basolateral side, ferroportin pumps iron into blood.
· Hepatocytes decide how much hepcidin to secrete based on whole-body iron stores (mainly transferrin saturation + how much iron the liver holds).
· Hepcidin is a 25-amino-acid peptide whose blood concentration directly regulates ferroportin.
· High iron → hepcidin rises → ferroportin is internalized and degraded → ferroportin count ↓ → enterocytes lock iron inside themselves → iron exits with shed enterocytes in stool.
· Low iron → hepcidin falls → ferroportin is retained → absorption rises.

Key player: HFE protein

· HFE is one of the iron-status sensors on the hepatocyte membrane.
· It cooperates with transferrin receptor 1 (TfR1): HFE-TfR1-transferrin tri-molecular recognition → tells the hepatocyte "whole-body iron is sufficient."
· The signal travels to hepcidin transcription factors (the BMP6 / SMAD pathway) → raises hepcidin → closes the gate.

In normal people: this loop works like a household thermostat — when iron is full, the gate shuts. Daily net absorption 1-2 mg = daily net loss 1-2 mg, balanced for life.

Next we see how this gate breaks, and how it does so with no alarm whatsoever.

2 · HFE C282Y mutation

The C282Y mutation makes HFE misfold and never reach the cell surface, so the liver reads iron as insufficient, hepcidin stays low and the gut keeps over-absorbing iron.The most common type of hereditary hemochromatosis (HH) is the HFE C282Y mutation — cysteine at position 282 (Cys) is replaced by tyrosine (Tyr).

Implications of the position:

· The disulfide bond formed by Cys282 is critical to HFE protein folding.
· Loss of Cys282 → HFE misfolds → retained and degraded in the ER → no HFE on the cell surface.
· Without HFE → can't correctly sense transferrin saturation → BMP6 / SMAD signaling defaults to "iron is insufficient".
· Hepcidin transcription stays low, even when whole-body iron is already excessive.

Physiological consequence:

· Ferroportin is always retained — never internalized.
· Daily net absorption rises to 3-6 mg (normal 1-2 mg).
· The extra 2-4 mg/day × 365 × decades = cumulative iron overload.

Genetics:

· Autosomal recessive: only C282Y homozygotes (two mutant copies) show disease.
· Northern European descent frequency: ~1/200-300 C282Y homozygotes, ~10% heterozygous carriers.
· Asian ancestry: extremely rare; African / Latin American ancestry: also far less common than in Northern European descent — one of the strongest known ethnic distribution disparities among common recessive disorders.
· Penetrance (mutation + actual disease): clearly higher in men than in women; the share who actually fall ill varies widely with how a study defines disease.

Important identification:

· C282Y heterozygotes (one copy): usually no disease, but may worsen when stacked with other iron-loading factors (heavy alcohol / chronic transfusion / certain anemias).
· H63D mutation: another HFE mutation — alone does not cause disease, but the C282Y/H63D compound heterozygote carries partial risk.

Next: this silent over-absorption accumulates for decades — where does the iron go?

3 · Lifetime deposit map

Iron is first stored silently in ; once storage overflows, free iron makes that damage organs, roughly in the order liver, joints, heart, pancreas, skin, pituitary.Iron accumulation is a slow, silent disaster. In the first 20-30 years of over-absorption, patients are typically completely asymptomatic — iron is quietly stuffed into and hemosiderin storage, invisible. Then storage limits are breached, "free iron" appears, and Fenton chemistry generates that damages target organs.

Deposition priority + clinical consequences (roughly in order of presentation):

① Liver (earliest, age 30-40)
· Iron first accumulates in hepatocyte ferritin (periportal hepatocytes first), while Kupffer cells stay relatively iron-poor → after overload → free-iron ROS → hepatocyte death + fibrosis.
· "Hepatomegaly + mildly elevated + unexplained cirrhosis" → progressing to hepatocellular carcinoma (once cirrhosis is established, HCC risk rises substantially, and is not fully eliminated by treatment — lifelong surveillance is needed).

② Joints (age 40-50)
· MCP joints (2nd-3rd MCP) involved early — this is the classic "handshake pain" of HH.
· Iron-loaded chondrocytes prematurely senesce → resembles osteoarthritis but with an unusual distribution.

③ Heart (age 40-60)
· Cardiac iron overload → restrictive cardiomyopathy + arrhythmias → eventually heart failure.
· Reversible if treated early, irreversible late.

④ Pancreas (age 50-60)
· Pancreatic β-cell iron overload → selective death → "bronze diabetes".
· The name comes from the combination: bronze skin + diabetes + cirrhosis = the classic triad.

⑤ Skin
· Combined melanin + iron deposition → whole-body bronze tone (especially sun-exposed areas).
· Not even like a tan — it's systemic, including areas covered by clothing.

⑥ Gonads / pituitary
· Iron deposits in the anterior pituitary → gonadotropins ↓ → in men: low testosterone + low libido + infertility; in women: amenorrhea + infertility.
· "Male fatigue + joint pain + low libido + unexplained ALT elevation": think HH and test.

Key time window:

· Symptom onset age 40-60 — but iron overload has been building for 20-30 years.
· This is why family history + early screening can completely change outcomes.
· An unscreened patient may not be diagnosed until cirrhosis / heart failure / diabetes, at which point the damage is irreversible.

Next: how to catch it before irreversible damage.

4 · Screening + phlebotomy

Screening for HH uses an iron panel and a genetic test, and phlebotomy started before cirrhosis and kept up for life gives a normal lifespan.HH is a fully treatable genetic disease, but only if caught early, and treatment is kept up for life. The treatment itself is almost counterintuitively simple.

Screening ladder (cheap to expensive):

① Step 1 · Iron panel (any routine workup can do this)
· Transferrin saturation > 45% + > 200 (men and women who no longer menstruate) / 150 (menstruating women) µg/L, the WHO 2020 line for iron-overload risk in otherwise healthy adults.
· High ferritin alone does not necessarily mean iron overload — it can also indicate inflammation / liver disease / metabolic syndrome. Both elevated together suggests HH.

② Step 2 · Genetic testing
· HFE C282Y / H63D genotype — once is enough for life.
· Recommended for: Northern European ancestry + unexplained elevation / early-onset arthritis / unexplained cardiomyopathy / hypogonadism / first-degree relative with HH.

③ Step 3 · Assess damage
· Liver MRI (T2*) for iron content — superior to liver biopsy.
· Liver biopsy only for fibrosis staging.

Treatment · Phlebotomy:

· Each 500 mL of blood drawn removes about 250 mg of iron → the bone marrow has to draw on iron stores to rebuild red cells.
· How often, and down to what level, is set by the doctor from blood tests: usually more often at first to bring the stores down (often a year or two), then maintenance every few months, for life.
· Few side effects — the same act as giving blood.

Timing of treatment determines outcome:

· Diagnosed + treated before cirrhosis: normal lifespan (equal to peers without HH).
· Diagnosed only after cirrhosis: treatment still helps, but substantially elevated HCC risk persists and needs lifelong surveillance.
· "No symptoms, no treatment": wrong — deposition is ongoing and damage continues to accumulate.

Clinical signals about iron supplements:

· Men + post-menopausal women: should not take iron-containing multivitamins / iron monotherapy without lab evidence of iron deficiency.
· Men's multivitamins typically don't contain iron — this is a deliberate, science-based design choice, not a cost cut.
· Children ingesting adult iron tablets (counted as elemental iron): < 20 mg/kg is usually non-toxic · 20-60 mg/kg is mild-to-moderate toxicity · > 60 mg/kg can be fatal.
· At or above 40 mg/kg, or with obvious / persisting symptoms → the child must be evaluated at a medical facility. A 325 mg ferrous sulfate tablet holds ~65 mg elemental iron, so for a 12 kg toddler 5 tablets already clear 20 mg/kg — remembering only the 60 band turns a child who needs care into "not there yet."
· If ingestion is suspected, do not wait at home for symptoms — call poison control / go to the emergency department. Iron tablets are one of the most common preventable pediatric drug poisonings; keep them absolutely out of children's reach.

Conclusion · The iron discipline:

① Check ferritin first · supplement second · don't supplement if not deficient.
② Men / post-menopausal women / Northern European ancestry + family history: think HFE genotype.
③ "Iron is good" becomes poison in HH — nutrients are not unidirectional, excess can harm, and individual variation can flip the cost-benefit.

Full mechanism, in text

1 · Normal HFE-hepcidin loop

2 · HFE C282Y mutation

3 · Lifetime deposit map

4 · Screening + phlebotomy

Iron overload · HFE C282Y · bronze diabetes

Full mechanism, in text

1 · Normal HFE-hepcidin loop

2 · HFE C282Y mutation

3 · Lifetime deposit map

4 · Screening + phlebotomy

Iron overload · HFE C282Y · bronze diabetes